Identification of four key biomarkers and small molecule drugs in nasopharyngeal carcinoma by weighted gene co-expression network analysis

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Pathmanathan R, et al. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. variants of epstein-barr virus-infected neoplasia. Am J Pathol. 1995;146(6):1355–1367.
   PubMed Web of Science ®Google Scholar
• Bensouda Y, Kaikani W, Ahbeddou N, et al. Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2011;128(2):79–85.
   PubMed Web of Science ®Google Scholar
• Henderson BE, Louie E, Jing SH, et al. Risk factors associated with nasopharyngeal carcinoma. N Engl J Med. 1976;295(20):1101–1106.
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Wakisaka N, Kondo S, et al. Progression of understanding for the role of epstein-barr virus and management of nasopharyngeal carcinoma. Cancer Metastasis Rev. 2017;36(3):435–447.
   PubMed Web of Science ®Google Scholar
• Nam JM, McLaughlin JK, Blot WJ. Cigarette smoking, alcohol, and nasopharyngeal carcinoma: a case-control study among U.S whites. J Natl Cancer Inst. 1992;84(8):619–622.
   PubMedGoogle Scholar
• Tsang CM, Tsao SW. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virol Sin. 2015;30(2):107–121.
   PubMed Web of Science ®Google Scholar
• Tsao SW, Tsang CM, To K-F, et al. The role of Epstein-Barr virus in epithelial malignancies. J Pathol. 2015;235(2):323–333.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang J, Zhang Z, et al. Epstein-barr virus-encoded products promote circulating tumor cell generation: a novel mechanism of nasopharyngeal carcinoma metastasis. Onco Targets Ther. 2019;12:11793–11804.
   PubMed Web of Science ®Google Scholar
• Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160270.
   PubMed Web of Science ®Google Scholar
• Chan AS, To KF, Lo KW, et al. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int J Cancer. 2002;102(3):300–303.
   PubMed Web of Science ®Google Scholar
• Bei J-XJ-X, Zuo X-Y, Liu W-S, et al. Genetic susceptibility to the endemic form of NPC. Chin Clin Oncol. 2016;5(2):15.
   PubMed Web of Science ®Google Scholar
• Bei JX, Jia WH, Zeng YX. Familial and large-scale case-control studies identify genes associated with nasopharyngeal carcinoma. Semin Cancer Biol. 2012;22(2):96–106.
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Wang CP. Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: rosetta stone for NPC: genetics, viral infection, and other environmental factors. Semin Cancer Biol. 2012;22(2):107–116.
   PubMed Web of Science ®Google Scholar
• Dai W, Zheng H, Cheung AKL et al. Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2016;113(12):3317–3322.
   PubMed Web of Science ®Google Scholar
• Yu G, Hsu W-L, Coghill AE, et al. Whole-exome sequencing of nasopharyngeal carcinoma families reveals novel variants potentially involved in nasopharyngeal carcinoma. Sci Rep. 2019;9(1):9916.
   PubMed Web of Science ®Google Scholar
• Cheung AKLAK, Ip JCY, Chu ACH et al. PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma. Oncotarget. 2015;6(15):13434–13447.
   PubMedGoogle Scholar
• Edgar R. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–210.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929–1935.
   PubMed Web of Science ®Google Scholar
• Li C, Yu S, Nakamura F, et al. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J Clin Invest. 2009;119(9):2725–2736.
   PubMed Web of Science ®Google Scholar
• Ho JC, Cheung ST, Patil M, et al. Increased expression of glycosyl-phosphatidylinositol anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinoma. Int J Cancer. 2006;119(6):1330–1337.
   PubMed Web of Science ®Google Scholar
• Jiang WW, Zahurak M, Zhou Z-T, et al. Alterations of GPI transamidase subunits in head and neck squamous carcinoma. Mol Cancer. 2007;6(1):74.
   PubMed Web of Science ®Google Scholar
• Amit M, Na’ara S, Francis D, et al. Post-translational regulation of radioactive iodine therapy response in papillary thyroid carcinoma. J Natl Cancer Inst. 2017;109(12). DOI:10.1093/jnci/djx092.
   PubMedGoogle Scholar
• Hurov J, Piwnica-Worms H. The par-1/MARK family of protein kinases: from polarity to metabolism. Cell Cycle. 2007;6(16):1966–1969.
   PubMed Web of Science ®Google Scholar
• Matenia D, Mandelkow EM. The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem Sci. 2009;34(7):332–342.
   PubMed Web of Science ®Google Scholar
• McDonald JA. Canonical and noncanonical roles of Par-1/MARK kinases in cell migration. Int Rev Cell Mol Biol. 2014;312:169–199.
   PubMed Web of Science ®Google Scholar
• Natalia MA, Alejandro G-T, Virginia T-VJ et al. MARK1 is a novel target for miR-125a-5p: implications for cell migration in cervical tumor cells. Microrna. 2018;7(1):54–61.
   PubMedGoogle Scholar
• Tang X, Yang M, Wang Z, et al. MicroRNA-23a promotes colorectal cancer cell migration and proliferation by targeting at MARK1. Acta Biochim Biophys Sin (Shanghai). 2019;51(7):661–668.
   PubMed Web of Science ®Google Scholar
• Zazo Seco C, Serrão de Castro L, van Nierop J, et al. Allelic mutations of KITLG, encoding KIT ligand, cause asymmetric and unilateral hearing loss and waardenburg syndrome type 2. Am J Hum Genet. 2015;97(5):647–660.
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Si LZ, Tang Q, et al. Gain-of-function mutation of KIT ligand on melanin synthesis causes familial progressive hyperpigmentation. Am J Hum Genet. 2009;84(5):54–61.
   Web of Science ®Google Scholar
• Yuzawa S, Opatowsky Y, Zhang Z, et al. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell. 2007;130(2):323–334.
   PubMed Web of Science ®Google Scholar
• Hirano K, Kitazawa  A, Kojima K, et al. Expression of stem cell factor (SCF), a KIT ligand, in gastrointestinal stromal tumors (GISTs): a potential marker for tumor proliferation. Pathol Res Pract. 2008;204(11):799–807.
   PubMed Web of Science ®Google Scholar
• Ulivi P, Zoli W, Medri L, et al. c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat. 2004;83(1):33–42.
   PubMed Web of Science ®Google Scholar
• Lammie A, Drobnjak M, Gerald W, et al. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994;42(11):1417–1425.
   PubMed Web of Science ®Google Scholar
• Chanock S. High marks for GWAS. Nat Genet. 2009;41(7):765–766.
   PubMed Web of Science ®Google Scholar
• Chen W, Li J, Liu C, et al. A functional p53 responsive polymorphism in KITLG, rs4590952, does not affect the risk of breast cancer. Sci Rep. 2014;4(1):6371.
   PubMed Web of Science ®Google Scholar
• Cousins RJ, Lanningham-Foster L. Regulation of cysteine-rich intestinal protein, a zinc finger protein, by mediators of the immune response. J Infect Dis. 2000;182(Suppl 1):S81–4.
   PubMed Web of Science ®Google Scholar
• Balluff B, Rauser S, Meding S, et al. MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol. 2011;179(6):2720–2729.
   PubMed Web of Science ®Google Scholar
• Zhang LZ, Huang L-Y, Huang A-L, et al. CRIP1 promotes cell migration, invasion and epithelial-mesenchymal transition of cervical cancer by activating the Wnt/β‑catenin signaling pathway. Life Sci. 2018;207:420–427.
   PubMed Web of Science ®Google Scholar
• Liu S, Hu Z, Zhang Q, et al. Co-Prodrugs of 7-Ethyl-10-hydroxycamptothecin and vorinostat with in vitro hydrolysis and anticancer effects. ACS Omega. 2020;5(1):350–357.
   PubMed Web of Science ®Google Scholar
• Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007;16(7):1111–1120.
   PubMed Web of Science ®Google Scholar
• Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 2008;269(1):7–17.
   PubMed Web of Science ®Google Scholar
• Han L, Wang T, Wu J, et al. A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy. Int J Nanomedicine. 2016;11:6003–6022.
   PubMed Web of Science ®Google Scholar
• Bruzzese F, Rocco M, Castelli S, et al. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther. 2009;8(11):3075–3087.
   PubMed Web of Science ®Google Scholar
• Hui KF, Ho DN, Tsang CM, et al. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer. 2012;131(8):1930–1940.
   PubMed Web of Science ®Google Scholar
• Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet. 2004;363(9423):1802–1811.
   PubMed Web of Science ®Google Scholar
• Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173(3):699–703.
   PubMed Web of Science ®Google Scholar
• Corral LG, Muller GW, Moreira AL, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med. 1996;2(4):506–515.
   PubMed Web of Science ®Google Scholar
• He Y, Mao R, Chen F, et al. Thalidomide induces clinical remission and mucosal healing in adults with active Crohn’s disease: a prospective open-label study. Therap Adv Gastroenterol. 2017;10(5):397–406.
   PubMed Web of Science ®Google Scholar
• Hu H, Wang X, Liu S. Thalidomide induces mucosal healing in postoperative crohn disease endoscopic recurrence: case report and literature review. Medicine (Baltimore). 2016;95(36):e4799.
   PubMed Web of Science ®Google Scholar
• Bauditz J. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active crohn’s disease. Gut. 2002;50(2):196–200.
   PubMed Web of Science ®Google Scholar
• Miyazato K, Tahara H, Hayakawa Y. Anti-metastatic effects of thalidomide by inducing the functional maturation of peripheral NK cells. Cancer Sci. 2020;111(8):2770–2778.
   Web of Science ®Google Scholar
• Wang A, Duan QH, Liu X, et al. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol. 2012;91(11):1779–1784.
   PubMed Web of Science ®Google Scholar
• Aguiar PM, de # T, Colleoni GWB et al. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: an overview of systematic reviews with meta-analyses. Crit Rev Oncol Hematol. 2017;113:195–212.
   PubMed Web of Science ®Google Scholar
• Cao DD, Xu H-L, Liu L, et al. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(27):44976–44993.
   PubMedGoogle Scholar
• Wang X, Shen Y, MengLv L, et al. Thalidomide suppresses breast cancer tumor growth by inhibiting tumor-associated macrophage accumulation in breast tumor-bearing mice. Eur J Pharm Sci. 2020;151:105302.
   PubMed Web of Science ®Google Scholar